Global /South Korea /Healthcare /Biotechnology /397030

AprilBio Co.,Ltd.

397030

• KRX: 397030 • Delayed

64,100KRW -0.3%

42.47 USD

As of 18 June 2026, AprilBio Co.,Ltd. has a market cap of $991.3M USD, ranking #10780 globally and #290 in South Korea. It ranks #959 in the Healthcare sector, and #184 in the Biotechnology industry.

Global Rank

10780

Country Rank

290

Sector Rank

959

Industry Rank

184

Key Stats

Market Cap

$991.3MUSD

1.5T KRW

Enterprise Value

$930.16MUSD

1.4T KRW

Revenue (TTM)

$1.44MUSD

2.17B KRW

EBITDA (TTM)

-$4.36MUSD

-6.57B KRW

Net Income (TTM)

-$6.44MUSD

-9.73B KRW

PS Ratio

688.9

PB Ratio

15.5

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Biotechnology

CEO

Sang-Hoon Cha open_in_new

Founded

2013

Website

aprilbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.3%	10%	1.1%	10%	113%	17%	315%	479%	377%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	397030 주식회사 에이프릴바이오 ISIN: KR7397030008 Shares Out.: Shares Outstanding: 23.414M¹ Shares Float: 17.459M² TV: TradingView: KRX: 397030 SA: Stock Analysis: KRX: 397030 YF: Yahoo Finance: 397030.KS GF: Google Finance: KRX: 397030 BA: Barron's: 397030 MS: Morningstar: XKRX: 397030	64,100 KRW	TV: TradingView: KRX: 397030 SA: Stock Analysis: KRX: 397030 YF: Yahoo Finance: 397030.KS GF: Google Finance: KRX: 397030 BA: Barron's: 397030 MS: Morningstar: XKRX: 397030

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About AprilBio Co.,Ltd.

AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Chuncheon-si, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Biologics Co.,Ltd. KRX: 207940	$45.17B 68.19T KRW 4K%	35.5	South Korea
Celltrion, Inc. KRX: 068270	$28.33B 42.76T KRW 3K%	43.8	South Korea
ALTEOGEN Inc. KRX: 196170	$13.47B 20.33T KRW 1K%	146.6	South Korea
HLB Co., Ltd. KRX: 028300	$5.55B 8.37T KRW 460%	-	South Korea
Peptron, Inc. KRX: 087010	$4.02B 6.07T KRW 306%	-	South Korea
SK bioscience Co.,Ltd. KRX: 302440	$2.27B 3.42T KRW 129%	-	South Korea

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 18K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 16K%	19.0	United States
argenx SE EBR: ARGX	$48.06B 41.39B EUR 5K%	39.9	Netherlands
CSL Ltd. ASX: CSL	$42.62B 60.27B AUD 4K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.51B 33.71B CHF 4K%	37.2	Switzerland
Natera, Inc. NASDAQ: NTRA	$27.6B 3K%	-	United States

chevron_leftBack